Ajer Jeffrey Robert — SEC insider filings
SEC reporting owner CIK 1557533. 38 insider filings on record with FilingPulse; latest filed 2026-09-25.
Transaction summary — filings shown
Covers all 38 filings on record, filed 2020-09-21 to 2026-09-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 24 legs across 21 filings — 110,949 shares, $9,525,084 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 44.
- Largest priced transaction: sale of 44,825 shares @ $115.65 ($5,184,191) in BIOMARIN PHARMACEUTICAL INC, filed 2023-01-27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | EVP, Chief Commercial Officer | 25 | — | 19 legs · 93,227 sh · $9,343,169 | 29 |
| NEKTAR THERAPEUTICS (NKTR) | Director | 10 | — | 5 legs · 17,722 sh · $181,915 | 12 |
| Viridian Therapeutics, Inc.\DE (VRDN) | Director | 3 | — | — | 3 |
Insider filings — Ajer Jeffrey Robert
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-25 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 2,000 @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Viridian Therapeutics, Inc.\DE (VRDN) | Grant/award (A): 32,341 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Viridian Therapeutics, Inc.\DE (VRDN) | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-04-09 | 4 | Viridian Therapeutics, Inc.\DE (VRDN) | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2024-05-06 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 300 @ $68.65 · Sale (S): 5,000 @ $82.91 | EDGAR |
| 2024-03-19 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Tax withholding (F): 22,580 @ $83.87 | EDGAR |
| 2024-03-07 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 4,000 @ $87.07 | EDGAR |
| 2024-02-29 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 21,440 @ $0 · Grant/award (A): 9,338 @ $0 · Grant/award (A): 6,465 @ $0 | EDGAR |
| 2023-09-20 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 4,359 @ $0.69 · Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2023-08-17 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 318 @ $66.88 · Sale (S): 5,000 @ $90 | EDGAR |
| 2023-03-17 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 10,110 @ $0 · Tax withholding (F): 3,971 @ $87.74 · Tax withholding (F): 20,510 @ $93.41 · Grant/award (A): 23,070 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 20,760 @ $0 · Grant/award (A): 10,380 @ $0 · Grant/award (A): 7,629 @ $0 | EDGAR |
| 2023-01-27 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Option exercise (M): 49,000 @ $67.81 · Sale (S): 44,825 @ $115.65 · Sale (S): 4,175 @ $116.15 · Option exercise (M): 2,200 (derivative) @ $0 · Option exercise (M): 46,800 (derivative) @ $0 | EDGAR |
| 2022-11-04 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 3,000 @ $86.12 | EDGAR |
| 2022-09-26 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 4,198 @ $3.16 | EDGAR |
| 2022-09-20 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 10,200 @ $0 · Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2022-08-12 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 3,000 @ $95.62 | EDGAR |
| 2022-06-07 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Tax withholding (F): 7,021 @ $77.49 | EDGAR |
| 2022-05-31 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 340 @ $62.41 · Sale (S): 1,308 @ $78.94 | EDGAR |
| 2022-04-14 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 1,180 @ $82.47 | EDGAR |
| 2022-03-31 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 1,618 @ $79.43 · Sale (S): 1,381 @ $79.56 | EDGAR |
| 2022-03-24 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 2,073 @ $81 · Sale (S): 6,129 @ $81.78 | EDGAR |
| 2022-03-17 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 11,940 @ $0 · Tax withholding (F): 8,418 @ $78.27 · Tax withholding (F): 1,287 @ $80.72 · Grant/award (A): 28,670 (derivative) @ $0 | EDGAR |
| 2022-03-10 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 9,370 @ $0 | EDGAR |
| 2021-10-28 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 342 @ $62.41 · Sale (S): 2,739 @ $73.60 | EDGAR |
| 2021-09-24 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 10,200 @ $0 · Sale (S): 3,665 @ $17.78 · Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2021-04-09 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 1,537 @ $78.81 | EDGAR |
| 2021-04-01 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 1,652 @ $74.79 | EDGAR |
| 2021-03-26 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 1,181 @ $76.30 | EDGAR |
| 2021-03-23 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Tax withholding (F): 1,513 @ $78.52 | EDGAR |
| 2021-03-19 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 1,308 @ $77.99 | EDGAR |
| 2021-03-17 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 10,720 @ $0 · Tax withholding (F): 5,273 @ $78.39 · Tax withholding (F): 1,287 @ $77.21 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2020-10-15 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 2,121 @ $79.91 | EDGAR |
| 2020-09-30 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 3,250 @ $17.25 | EDGAR |
| 2020-09-25 | 4/A | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 9,100 @ $0 · Grant/award (A): 18,200 (derivative) @ $0 | EDGAR |
| 2020-09-24 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 9,100 @ $0 · Grant/award (A): 18,200 (derivative) @ $0 | EDGAR |
| 2020-09-21 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 2,250 @ $19.74 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1557533 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs